Investigational Drug Information for Chiglitazar
✉ Email this page to a colleague
What is the development status for investigational drug Chiglitazar?
Chiglitazar is an investigational drug.
There have been 10 clinical trials for Chiglitazar.
The most recent clinical trial was a Phase 3 trial, which was initiated on September 1st 2014.
The most common disease conditions in clinical trials are Diabetes Mellitus, Diabetes Mellitus, Type 2, and Syndrome. The leading clinical trial sponsors are Chipscreen Biosciences, Ltd., Affiliated Hospital of Nantong University, and Shengjing Hospital.
Summary for Chiglitazar
US Patents | 0 |
International Patents | 0 |
US Patent Applications | 129 |
WIPO Patent Applications | 134 |
Japanese Patent Applications | 46 |
Clinical Trial Progress | Phase 3 (2014-09-01) |
Vendors | 24 |
Recent Clinical Trials for Chiglitazar
Title | Sponsor | Phase |
---|---|---|
A Prospective, Open, Self-controlled Study of the Effects of Chiglitazar Sodium on Glucose and Lipid Metabolism in Patients With Type 2 Diabetes Mellitus (T2DM) | Yufan Wang | N/A |
Chiglitazar/Metformin in Non-obese Women With PCOS | Shengjing Hospital | Phase 2/Phase 3 |
Drug-Drug Interaction Study of Chiglitazar in Healthy Subjects. | Chipscreen Biosciences, Ltd. | Phase 1 |
Clinical Trial Summary for Chiglitazar
Top disease conditions for Chiglitazar
Top clinical trial sponsors for Chiglitazar
US Patents for Chiglitazar
Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
---|---|---|---|---|
>Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |